A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.

Hematology (Amsterdam, Netherlands)(2023)

Cited 0|Views6
No score
Abstract
The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials.
More
Translated text
Key words
Relapsed-refractory multiple myeloma,daratumumab,monoclonal antibodies,real-world,standard of care
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined